{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:08:35Z","timestamp":1791590915496,"version":"4.3.4"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFC2501700"],"award-info":[{"award-number":["2021YFC2501700"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019018","name":"Chinese Academy of Medical Sciences Initiative for Innovative Medicine","doi-asserted-by":"publisher","award":["2021-I2M-1-002"],"award-info":[{"award-number":["2021-I2M-1-002"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970757"],"award-info":[{"award-number":["81970757"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270938"],"award-info":[{"award-number":["82270938"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","award":["2023-PT320-10"],"award-info":[{"award-number":["2023-PT320-10"]}],"id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.eclinm.2025.103329","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T22:51:02Z","timestamp":1751583062000},"page":"103329","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Efficacy and safety of narlumosbart, an anti-RANKL monoclonal antibody, in postmenopausal women with osteoporosis: a multi-center, randomized, double-blind, placebo- and active-controlled, phased II study"],"prefix":"10.1016","volume":"85","author":[{"given":"Yue","family":"Chi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanqing","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhong","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Difei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiping","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baofang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhufeng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weibo","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.eclinm.2025.103329_bib1","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.ecl.2012.04.006","article-title":"Pathophysiology of osteoporosis: new mechanistic insights","volume":"41","author":"Armas","year":"2012","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"21","key":"10.1016\/j.eclinm.2025.103329_bib2","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1056\/NEJMcp2307353","article-title":"Postmenopausal osteoporosis","volume":"389","author":"Walker","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103329_bib3","first-page":"509","article-title":"[Prevalence of osteoporosis and related factors in postmenopausal women aged 40 and above in China]","volume":"43","author":"Tang","year":"2022","journal-title":"Zhonghua Liu Xing Bing Xue Za Zhi"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103329_bib4","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1080\/13697137.2021.1951206","article-title":"Osteoporosis and fractures in women: the burden of disease","volume":"25","author":"Lorentzon","year":"2022","journal-title":"Climacteric"},{"issue":"11","key":"10.1016\/j.eclinm.2025.103329_bib5","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.tem.2012.05.005","article-title":"New insights into osteoclastogenic signaling mechanisms","volume":"23","author":"Nakashima","year":"2012","journal-title":"Trends Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103329_bib6","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1152\/physrev.00036.2016","article-title":"Osteoimmunology: the conceptual framework unifying the immune and skeletal systems","volume":"97","author":"Okamoto","year":"2017","journal-title":"Physiol Rev"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103329_bib7","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.molmed.2005.11.007","article-title":"RANKL-RANK signaling in osteoclastogenesis and bone disease","volume":"12","author":"Wada","year":"2006","journal-title":"Trends Mol Med"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103329_bib8","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1210\/er.2007-0014","article-title":"Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease","volume":"29","author":"Kearns","year":"2008","journal-title":"Endocr Rev"},{"issue":"7722","key":"10.1016\/j.eclinm.2025.103329_bib9","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/s41586-018-0482-7","article-title":"Coupling of bone resorption and formation by RANKL reverse signalling","volume":"561","author":"Ikebuchi","year":"2018","journal-title":"Nature"},{"issue":"Suppl 1","key":"10.1016\/j.eclinm.2025.103329_bib10","doi-asserted-by":"crossref","DOI":"10.1186\/ar2165","article-title":"Biology of RANK, RANKL, and osteoprotegerin","volume":"9 Suppl 1","author":"Boyce","year":"2007","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103329_bib11","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.abb.2008.03.018","article-title":"Functions of RANKL\/RANK\/OPG in bone modeling and remodeling","volume":"473","author":"Boyce","year":"2008","journal-title":"Arch Biochem Biophys"},{"issue":"8","key":"10.1016\/j.eclinm.2025.103329_bib12","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103329_bib13","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/GME.0b013e318267f909","article-title":"Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis: bone density, mass, and strength of the radius, and wrist fracture","volume":"20","author":"Simon","year":"2013","journal-title":"Menopause"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103329_bib14","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bone.2008.04.007","article-title":"Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial","volume":"43","author":"Miller","year":"2008","journal-title":"Bone"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103329_bib15","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1210\/jc.2010-1502","article-title":"Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass","volume":"96","author":"Bone","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.eclinm.2025.103329_bib16","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/jbmr.448","article-title":"Bone remodeling in postmenopausal women who discontinued denosumab treatment: off-treatment biopsy study","volume":"26","author":"Brown","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103329_bib17","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00198-015-3380-y","article-title":"Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports","volume":"27","author":"Aubry-Rozier","year":"2016","journal-title":"Osteoporos Int"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103329_bib18","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1210\/jc.2016-3170","article-title":"Severe rebound-associated vertebral fractures after denosumab discontinuation: 9 clinical cases report","volume":"102","author":"Lamy","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103329_bib19","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103329_bib20","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1210\/jc.2018-01965","article-title":"Invasive oral procedures and events in postmenopausal women with osteoporosis treated with denosumab for up to 10 years","volume":"104","author":"Watts","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103329_bib21","doi-asserted-by":"crossref","first-page":"9541","DOI":"10.1038\/s41467-024-53686-4","article-title":"Efficacy and safety of JMT103 in patients with unresectable or surgically-challenging giant cell tumor of bone: a multicenter, phase Ib\/II study","volume":"15","author":"Xu","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.eclinm.2025.103329_bib22","article-title":"Safety, tolerability, and pharmacokinetics\/pharmacodynamics of JMT103 in patients with bone metastases from solid tumors","volume":"12","author":"Liang","year":"2022","journal-title":"Front Oncol"},{"issue":"16_suppl","key":"10.1016\/j.eclinm.2025.103329_bib23","doi-asserted-by":"crossref","first-page":"e15190","DOI":"10.1200\/JCO.2024.42.16_suppl.e15190","article-title":"A phase Ib study of JMT103, a receptor activator of NF-kB ligand (RANKL) antibody, in patients (pts) with bone metastases from solid tumors","volume":"42","author":"Ran","year":"2024","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103329_bib24","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s00198-011-1786-8","article-title":"Dose-response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis","volume":"23","author":"Nakamura","year":"2012","journal-title":"Osteoporos Int"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103329_bib25","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1359\/jbmr.0809010","article-title":"Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial","volume":"24","author":"Brown","year":"2009","journal-title":"J Bone Miner Res"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103329_bib26","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/jbmr.251","article-title":"Effects of denosumab on bone turnover markers in postmenopausal osteoporosis","volume":"26","author":"Eastell","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103329_bib27","doi-asserted-by":"crossref","first-page":"e1951","DOI":"10.1210\/clinem\/dgae611","article-title":"Proposed denosumab biosimilar SB16 vs reference denosumab in postmenopausal osteoporosis: phase 3 results up to month 12","volume":"110","author":"Langdahl","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103329_bib28","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/s41401-022-00954-y","article-title":"A phase III randomized, double-blind, placebo-controlled trial of the denosumab biosimilar QL1206 in postmenopausal Chinese women with osteoporosis and high fracture risk","volume":"44","author":"Zhang","year":"2023","journal-title":"Acta Pharmacol Sin"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103329_bib29","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.bone.2011.08.007","article-title":"A randomized, double-blind, placebo-controlled, single-dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of denosumab administered subcutaneously to postmenopausal Japanese women","volume":"49","author":"Kumagai","year":"2011","journal-title":"Bone"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103329_bib30","first-page":"243","article-title":"Paracrine regulation of osteoclast formation and activity: milestones in discovery","volume":"4","author":"Martin","year":"2004","journal-title":"J Musculoskelet Neuronal Interact"},{"issue":"8","key":"10.1016\/j.eclinm.2025.103329_bib31","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1056\/NEJMe068003","article-title":"The long and the short of bone therapy","volume":"354","author":"Whyte","year":"2006","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103329_bib32","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s13181-016-0543-y","article-title":"A RANKL wrinkle: denosumab-induced hypocalcemia","volume":"12","author":"Laskowski","year":"2016","journal-title":"J Med Toxicol"},{"issue":"9","key":"10.1016\/j.eclinm.2025.103329_bib33","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1185\/03007995.2013.813840","article-title":"Incidence and risk of denosumab-related hypocalcemia in cancer patients: a systematic review and pooled analysis of randomized controlled studies","volume":"29","author":"Qi","year":"2013","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103329_bib34","doi-asserted-by":"crossref","first-page":"e305","DOI":"10.1016\/j.clgc.2014.11.008","article-title":"Severe hypocalcemia associated with denosumab in metastatic castration-resistant prostate cancer: risk factors and precautions for treating physicians","volume":"13","author":"Autio","year":"2015","journal-title":"Clin Genitourin Cancer"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103329_bib35","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/s41591-024-02822-0","article-title":"RANKL blockade for erosive hand osteoarthritis: a randomized placebo-controlled phase 2a trial","volume":"30","author":"Wittoek","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.eclinm.2025.103329_bib36","series-title":"Physiology, parathyroid hormone. StatPearls. Treasure Island (FL): StatPearls publishing copyright \u00a9 2024","author":"Khan","year":"2024"},{"issue":"50","key":"10.1016\/j.eclinm.2025.103329_bib37","doi-asserted-by":"crossref","first-page":"48868","DOI":"10.1074\/jbc.M208494200","article-title":"Parathyroid hormone stimulates receptor activator of NFkappa B ligand and inhibits osteoprotegerin expression via protein kinase a activation of cAMP-response element-binding protein","volume":"277","author":"Fu","year":"2002","journal-title":"J Biol Chem"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025002615?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025002615?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T13:41:17Z","timestamp":1768830077000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537025002615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":37,"alternative-id":["S2589537025002615"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103329","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of narlumosbart, an anti-RANKL monoclonal antibody, in postmenopausal women with osteoporosis: a multi-center, randomized, double-blind, placebo- and active-controlled, phased II study","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103329","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103329"}}